LL

Larry Lasky

Partner at The Column Group

Sausalito, California

Overview 

Larry Lasky is a Partner at The Column Group in Sausalito, California, with a background in venture capital focusing on biotechnology and life sciences. His career highlights include investing in companies like Accent Therapeutics and Revolution Medicines, as well as holding key roles at Genentech and USVP. Lasky's current role as a Partner at The Column Group involves investing in various stages and sectors within the biotech industry, showcasing his expertise in due diligence, entrepreneurship, and drug discovery.

Work Experience 

TC

The Column Group

  • Partner

    2014 - Current

    I will continue to invest in early stage therapeutic biotech companies focused on severe diseases. I have made investments in eFFector Pharmaceuticals and was a co-founder of Ribon therapeutics.

U

USVP

  • Partner

    2008 - 2014

    Leader of biotech investment area. Invested in Intellikine (acquired by Takeda/MLNM), founding or co-founding investor of Calithera Pharmaceuticals, Cleave Biosciences and eFFector Pharmaceuticals. Founding investor of Proteolix (acquired by Onyx) and Oncomed (Nasdaq: OMED).

UB

UC Berkeley

  • Lecturer

    2006 - 2012

    Taught biotechnology entrepreneurship course.

Latterell Venture Partners

  • General Partner

    2002 - 2008

    Founding partner. Founding investor of several successful companies including Cellective (acquired by Medimmune), Proteolix (acquired by Onyx) and Oncomed (Nasdaq: OMED).

G

Genentech

  • Scientist, Senior Scientist, Staff Scientist, Genentech Fellow

    1982 - 2002

    Genentech Fellow is the highest scientific position in the company. There have been 3 Genentech Research Fellows in the history of the company.

Genentech specializes in genetic testing and personalized medicine.

gene.com

Genetics Institute

  • Senior Scientist

    1981 - 1982

    Founding scientist. Initiated the GM CSF and bone morphogenetic protein projects.

Education 

Investments 

Accent Therapeutics

Series A

Total funding: $180M

Eikon Therapeutics

Series A

Total funding: $670M

Revolution Medicines

Series A

Total funding: $180M

Cleave Therapeutics

Series A

Total funding: $100M

Articles About Larry

Relevant Websites